Page 37 - MI-2-2
P. 37

Microbes & Immunity                                                     Genetic therapy with HSV-1 vectors



            References                                         14.  Aurelian L. HSV-induced apoptosis in herpes encephalitis.
                                                                  Curr Top Microbiol Immunol. 2005;289:79-111.
            1.   McGeoch  DJ,  Dalrymple  MA,  Davison  AJ,  et al.  The
               complete DNA sequence of the long unique region in      doi: 10.1007/3-540-27320-4_4
               the genome of herpes simplex virus type  1.  J  Gen Virol.   15.  Whitley  RJ,  Roizman  B.  Herpes  simplex  virus  infections.
               1988;69(Pt 7):1531-1574.                           Lancet. 2001;357(9267):1513-1518.
               doi: 10.1099/0022-1317-69-7-1531                   doi: 10.1016/S0140-6736(00)04638-9
            2.   Roizman B, Baines J. The diversity and unity of Herpesviridae.   16.  Daheshia M, Feldman LT, Rouse BT. Herpes simplex virus
               Comp Immunol Microbiol Infect Dis. 1991;14(2):63-79.  latency and the immune response.  Curr Opin Microbiol.
               doi: 10.1016/0147-9571(91)90122-t                  1998;1(4):430-435.

            3.   Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex      doi: 10.1016/s1369-5274(98)80061-1
               viruses. Clin Infect Dis. 1998;26(3):541-553; quiz 554-5.  17.  Arduino PG, Porter SR. Herpes simplex virus type  1
            4.   Marozin S, Prank U, Sodeik B. Herpes simplex virus type 1   infection: Overview on relevant clinico-pathological
               infection of polarized epithelial cells requires microtubules   features. J Oral Pathol Med. 2008;37(2):107-121.
               and access to receptors present at cell-cell contact sites.      doi: 10.1111/j.1600-0714.2007.00586.x
               J Gen Virol. 2004;85(Pt 4):775-786.
                                                               18.  Roizman B. HSV gene functions: What have we learned that
               doi: 10.1099/vir.0.19530-0                         could be generally applicable to its near and distant cousins?
            5.   Babb R, Huang CC, Aufiero DJ, Herr W. DNA recognition by   Acta Virol. 1999;43(2-3):75-80.
               the herpes simplex virus transactivator VP16: A novel DNA-  19.  Advani SJ, Weichselbaum RR, Whitley RJ, Roizman B. Friendly
               binding structure. Mol Cell Biol. 2001;21(14):4700-4712.  fire: Redirecting herpes simplex virus-1 for therapeutic
               doi: 10.1128/MCB.21.14.4700-4712.2001              applications. Clin Microbiol Infect. 2002;8(9):551-563.
            6.   Watanabe D. Medical application of herpes simplex virus.      doi: 10.1046/j.1469-0691.2002.00432.x.
               J Dermatol Sci. 2010;57(2):75-82.               20.  Goins WF, Wolfe D, Krisky DM, et al. Delivery using herpes

               doi: 10.1016/j.jdermsci.2009.10.014                simplex virus: An overview. Methods Mol Biol. 2004;246:257-299.
            7.   Boehmer PE, Lehman IR. Herpes simplex  virus DNA      doi: 10.1385/1-59259-650-9:257
               replication. Annu Rev Biochem. 1997;66:347-384.  21.  Epstein AL. HSV-1-derived recombinant and amplicon
               doi: 10.1146/annurev.biochem.66.1.347              vectors for preventive or therapeutic gene transfer: An
                                                                  overview. Gene Ther. 2005;12 Suppl 1:S153.
            8.   Roizman B. The function of herpes simplex virus genes:
               A primer for genetic engineering of novel vectors. Proc Natl   22.  Maguire-Zeiss KA, Bowers WJ, Federoff HJ. HSV vector-
               Acad Sci U S A. 1996;93(21):11307-11312.           mediated gene delivery to the central nervous system. Curr
                                                                  Opin Mol Ther. 2001;3(5):482-490.
               doi: 10.1073/pnas.93.21.11307
                                                               23.  Glorioso JC, Fink DJ. Herpes vector-mediated gene transfer
            9.   Elliott G, O’Hare P. Cytoplasm-to-nucleus translocation of   in treatment of diseases of the nervous system. Annu Rev
               a herpesvirus tegument protein during cell division. J Virol.   Microbiol. 2004;58:253-271.
               2000;74(5):2131-2141.
                                                                  doi: 10.1146/annurev.micro.58.030603.123709
               doi: 10.1128/jvi.74.5.2131-2141.2000
                                                               24.  Markert JM, Gillespie GY, Weichselbaum RR, Roizman B,
            10.  Jackson SA, DeLuca NA. Relationship of herpes simplex virus   Whitley RJ. Genetically engineered HSV in the treatment of
               genome configuration to productive and persistent infections.   glioma: A review. Rev Med Virol. 2000;10(1):17-30.
               Proc Natl Acad Sci U S A. 2003;100(13):7871-7876.
                                                                  doi: 10.1002/(sici)1099-1654(200001/02)10:1<17:aid-rmv2
               doi: 10.1073/pnas.1230643100
                                                                  58>3.0.co;2-g
            11.  Steiner I, Kennedy PG. Molecular biology of herpes simplex   25.  Niranjan A, Wolfe D, Fellows W,  et al. Gene transfer to
               virus type 1 latency in the nervous system. Mol Neurobiol.   glial tumors using herpes simplex virus. Methods Mol Biol.
               1993;7(2):137-159.
                                                                  2004;246:323-337.
               doi: 10.1007/BF02935640
                                                                  doi: 10.1385/1-59259-650-9:323
            12.  Roizman B, Whitley RJ. The nine ages of herpes simplex   26.  Karpoff  HM,  Kooby  D,  D’Angelica  M,  et al.  Efficient
               virus. Herpes. 2001;8(1):23-27.
                                                                  cotransduction of tumors by multiple herpes simplex
            13.  Rouse BT. Pathogenesis of the herpesviruses. Lab Anim Sci.   vectors: Implications for tumor vaccine production. Cancer
               1993;43(1):11-14.                                  Gene Ther. 2000;7(4):581-588.


            Volume 2 Issue 2 (2025)                         29                               doi: 10.36922/mi.7947
   32   33   34   35   36   37   38   39   40   41   42